Connect with us

Pregnancy

NIPT or NT scan? Why the 2026 evidence supports doing Both

Published

on

Article produced in association with London Pregnancy Clinic

One of the most common questions in early pregnancy: NIPT or the nuchal translucency (NT) scan – do I really need both? The 2026 evidence gives a clear answer.

The two tests look at different things, and doing them together is how first-trimester screening works at its best.

This is not a debate between old and new technology. NIPT is a genuine advance in detecting chromosome abnormalities from a maternal blood sample.

The NT scan is the first detailed look at how the fetus is forming. What each sees, the other largely cannot.

What NIPT actually tells you

NIPT – non-invasive prenatal testing – analyses fragments of fetal DNA circulating in the mother’s blood. Taken from around 10 weeks, the test measures chromosome proportions to flag the common trisomies: trisomy 21 (Down syndrome), trisomy 18 (Edwards) and trisomy 13 (Patau).

Most panels include fetal sex and sex-chromosome aneuploidies. Extended NIPT adds selected microdeletion syndromes – most commonly 22q11.2 (DiGeorge syndrome) – and the newest whole-genome platforms can detect copy-number variants down to around 1 Mb across every chromosome.

What NIPT does not look at is anatomy. It tells you whether the chromosomes are numerically correct.

It cannot tell you how the heart, brain, spine, kidneys or abdominal wall are forming, because it analyses DNA, not structure.

The NHS offers NIPT as a second-line screening test, reserved for women who receive a higher-chance result from the combined test – precisely because NIPT is best understood as one part of a wider screening picture rather than the whole of it.

What the NT scan actually tells you

The NT scan is an ultrasound performed at 11 to 14 weeks that measures the nuchal translucency – a small fluid-filled space at the back of the fetal neck.

Protocols developed by the Fetal Medicine Foundation, the group that pioneered first-trimester screening under Professor Kypros Nicolaides at King’s College Hospital, combine the NT measurement with additional markers: nasal bone, ductus venosus flow, tricuspid regurgitation, and maternal serum biomarkers (PAPP-A and free β-hCG).

More importantly, the scan is the first structural assessment of the fetus.

Major anomalies already visible at 11-14 weeks include absence of the cranial vault, large body-wall defects such as omphalocele and gastroschisis, megacystis, severe cardiac defects with abnormal four-chamber views, and skeletal dysplasias.

An increased NT measurement itself – even with a completely normal chromosome result – is associated with a notable rate of structural heart defects and monogenic syndromes that NIPT cannot detect.

Why the combination outperforms either test alone

Taken together, NIPT and the NT scan give complementary coverage.

For the common trisomies, NIPT is more sensitive than the NT scan alone. Pooled data place detection of trisomy 21 above 99 per cent with a false-positive rate around 0.1 per cent.

Combined first-trimester screening without NIPT, using NT and serum markers alone, reaches approximately 90 per cent detection – and up to 95 per cent when nasal bone, ductus venosus and tricuspid flow are added – at a 3 to 5 per cent false-positive rate.

For that specific endpoint, NIPT is the more accurate test.

The NT scan picks up almost everything NIPT misses: structural anomalies, early markers of monogenic syndromes, confirmation of viability, accurate dating, twin chorionicity, and placental position.

An increased NT with a normal NIPT result shifts the clinical conversation toward syndromes like Noonan, Kabuki and the skeletal dysplasias – conditions with single-gene origins rather than chromosomal ones.

Working out which is which often requires genetic testing beyond NIPT. Carrier screening and expanded genetic panels – including those offered at Jeen Health – cover the single-gene territory that NIPT does not address.

When the combination matters most

Several patient groups have most to gain from doing both:

  • Women conceiving after IVF or with donor gametes, where maternal age and fertility treatment each subtly shift risk profiles
  • Women aged 35 and over, where baseline chromosomal risk is higher and soft markers are more likely
  • Anyone with a previous pregnancy affected by an anomaly or loss, where reassurance matters
  • Twin pregnancies, where NIPT performance depends on fetal fraction and structural assessment is more complex
  • Women who have had a raised or borderline result on earlier screening markers

Chromosomes and anatomy are two separate clinical questions. Each needs its own answer.

What happens if the tests disagree

Disagreements between NIPT and the NT scan are not failures of either test – they are the reason both are done.

  • NIPT low-risk, NT raised: consider monogenic syndromes, structural cardiac assessment, and early anomaly ultrasound follow-up
  • NIPT higher-chance, scan normal: confirmatory diagnostic testing (CVS or amniocentesis) before any major decision
  • NIPT no-call: repeat sampling, gestational age check and clinical review – a no-call itself is associated with an increased chromosomal risk
  • Both abnormal: a clear indication for specialist fetal medicine review and early diagnostic testing

Professional guidance from the RCOG supports this complementary approach, emphasising that NIPT is a screening rather than a diagnostic test, and that its results are most useful when interpreted alongside ultrasound findings.

Practical guidance for 2026

The most efficient way to run both tests is in a single appointment window, between 10 and 14 weeks, with the blood sample taken first and the scan performed on the same visit.

Results typically return within 5 to 10 working days for standard NIPT panels, and same-day for the scan itself.

This is the logic behind the SMART Test at London Pregnancy Clinic – extended NIPT paired with a full first-trimester ultrasound in a single appointment, delivering both chromosomal and structural information in one visit. For most patients, it removes the false choice of picking one over the other.

The wider picture

The question of NIPT versus NT scan has a settled clinical answer in 2026: the two tests examine different aspects of the pregnancy, and the most complete first-trimester assessment uses both.

For a pregnancy a woman wants to carry with the fullest possible picture, both tests belong in the first-trimester window. The question worth asking is which clinic offers them together, with the pre- and post-test care that makes the results usable.

If you are deciding on first-trimester screening, a consultation with a fetal medicine specialist is the most useful first step.

Disclaimer: This article is produced for informational purposes only and does not constitute medical advice, diagnosis or treatment. Clinical guidance referenced reflects published NHS, Fetal Medicine Foundation and RCOG standards as at April 2026. Individual circumstances vary; readers are advised to consult a qualified healthcare professional before acting on any information in this article. This piece was produced in association with London Pregnancy Clinic, which provided background clinical information for editorial purposes. Hyperlinks to external sources are included for reference only and do not represent an endorsement of any product, service or organisation.

Pregnancy

£50m initiative aims to tackle disparities in maternal healthcare

Published

on

A £50m maternity consortium will bring together UK clinicians, researchers and communities to tackle the most critical gaps in maternal care.

Funding from the National Institute for Health and Care Research has established the NIHR Inequalities Challenge: Maternity Disparities Consortium under the leadership of the University of Birmingham and Newcastle University.

Higher education bodies, NHS organisations, community groups and voluntary organisations from across the UK will work together through the programme.

The NIHR has committed £50m over five years to support research led by clinicians, researchers and communities across the consortium.

Professor Joht Singh Chandan, consortium co-lead for research at the University of Birmingham, said: “National attention on maternity safety and equity has never been greater, but ambition must now be matched by evidence and implementation.

“Through this consortium, we will work across the UK to understand what works, for whom and in what contexts, and to ensure that research leads to practical changes in care for the women, babies and families who need them most.”

The launch comes at a pivotal moment for UK maternity care, with growing national attention on improving safety, equity and women’s experiences of care.

The government’s renewed Women’s Health Strategy highlights the need to improve care before and between pregnancies for underserved communities.

Against that backdrop, the consortium will generate the evidence, interventions and research capacity needed to help turn national ambition into practical improvements for women, babies and families.

University of Birmingham is leading work to improve maternity care pathways across the antenatal, intrapartum and postnatal periods.

Antenatal care covers pregnancy before labour, while intrapartum care refers to care during labour and birth.

The consortium will examine how women and families can be better supported before pregnancy and between pregnancies.

This includes improving access to advice and care that can help people prepare for pregnancy, manage existing health conditions and reduce risks before they build up.

Other research will focus on improving care during pregnancy, birth and the early weeks after birth.

This will include work on major causes of poor maternal health, such as high blood pressure, diabetes in pregnancy, obesity, perinatal mental health and complications during recovery after birth.

Professor Judith Rankin OBE, consortium co-lead for research and capacity development at Newcastle University, said: “This funding represents a critical opportunity to make the step change we need to improve outcomes for women and their babies.

“Alongside the research, the Consortium will be investing in tomorrow’s research leaders today to ensure we have the capacity to deliver on improving pregnancy outcomes, access to, and experience of, care.”

Continue Reading

Pregnancy

Liverpool uni secures £18.m for women’s health studio and life-saving tech

Published

on

The University of Liverpool has secured £1.8m to test a device for postpartum bleeding and launch a new women’s health studio.

The PPH Butterfly is designed to help control postpartum haemorrhage, which is severe bleeding after childbirth and a leading cause of maternal death worldwide.

The funding will support research into how the device can be used in clinical practice and generate evidence to inform its wider adoption.

The university has launched the Women’s Health Innovation Studio, known as the WIN Studio, alongside the project.

The £1.8m initiative is predominantly funded by the National Institute for Health and Care Research, which is providing £1.5m, with additional support from the university.

The PPH Butterfly project will involve a multi-centre clinical trial across the UK and a global feasibility study looking at how practical it would be to use the device in different healthcare settings.

The WIN Studio is led by Andrew Weeks, professor of international maternal health care at the University of Liverpool and a senior investigator at the National Institute for Health and Care Research, and Dr Teesta Dey, a tenure track fellow in the department of women’s and children’s health.

Dr Dey will also lead the PPH Butterfly project.

Its work will cover conditions linked to female biology, including endometriosis, menopause and pregnancy-related complications.

It will also support technologies for diseases that affect women differently or disproportionately, even when they are not usually classed as gender-specific conditions.

Dr Dey said: “Women’s health has often been marginalised within healthcare systems and innovation markets, resulting in treatments, devices and care models that fail to adequately account for women’s specific needs. WIN Studio seeks to change this status quo and reconfigure how health technologies are conceived and delivered.

“The funding from NIHR for this £1.8m project is precisely the kind of innovation the WIN Studio exists to foster: clinically urgent, women-centred, and with the potential to save lives at scale.”

The studio recently hosted an event at Liverpool Women’s University Hospital as part of the Liverpool City Region Combined Authority’s Innovation Investment Fortnight.

Seven innovations are currently undergoing clinical testing through the studio, with three developed internally.

The studio will work closely with NHS University Hospitals Liverpool Group and provide clinical, regulatory and commercial support to people developing women’s health technologies.

It will also involve patients and members of the public in shaping research priorities and product development.

Its wider programme includes collaborations involving clinicians, engineers, economists, academics and policymakers.

The project team says the PPH Butterfly is a simple, low-cost device designed to control severe bleeding quickly and with minimal training.

According to the team, postpartum haemorrhage causes around 70,000 deaths globally each year, equal to about one death every seven minutes.

The device previously received £1.1m in funding from the National Institute for Health and Care Research.

The latest £1.5m grant will support a randomised UK trial, in which participants are allocated to different treatment groups by chance, and a global feasibility assessment.

Weeks said: “In an area where women face deep health inequalities, WIN Studio has a vital role to play. By working in partnership with the NHS, local government and communities, we can ensure that research leads to real-world impact.

“Liverpool has a highly integrated ecosystem of academic, clinical and commercial expertise. By bringing these together under a single platform, the WIN Studio aims to act as a national exemplar for equitable health innovation. Transforming the way medical technologies are developed is essential to addressing gender disparities in healthcare outcomes.”

Another product supported by the university, the LifeStart Trolley, has already reached commercialisation.

The small mobile resuscitation trolley allows newborn care to be carried out at the bedside while the baby’s umbilical cord remains intact, enabling delayed cord clamping.

Delayed cord clamping means waiting before cutting the cord so blood can continue flowing from the placenta to the baby after birth.

Clinical trials conducted around 10 years ago found that life-saving care could be provided successfully at the bedside using the trolley.

It was later commercialised by Inspiration Healthcare and is now used in more than 70 UK maternity units and in 36 countries, including Norway, Italy and the US.

Continue Reading

Pregnancy

Type 2 diabetes raising twice as fast in younger womem, research finds

Published

on

Type 2 diabetes diagnoses are rising twice as fast in women under 40 as in women over 40, new data shows.

Type 2 diabetes is a serious condition and can lead to complications such as heart attacks and strokes. When it develops in younger people, it can be more aggressive and have more severe and acute effects.

Diagnoses in women under 40 rose by 47 per cent between 2017/18 and 2023/24. By comparison, diagnoses rose by 22 per cent in women aged 40 to 79.

During the same period, type 2 diabetes diagnoses in men under 40 increased by 34 per cent.

Diabetes UK said it is concerned about the follow-up care offered to women who have had gestational diabetes, also known as GDM, which increases the risk of developing type 2 diabetes after pregnancy.

Gestational diabetes is high blood sugar that develops during pregnancy and usually goes away after birth, but it raises the risk of type 2 diabetes later.

Colette Marshall, chief executive at Diabetes UK, said: “These figures should be a wake-up call. Type 2 diabetes is rising twice as fast in younger women compared to older women, and a crucial opportunity for prevention is being missed. Every diagnosis is life-changing, but when it develops in younger people, type 2 diabetes is even more aggressive.

“Pregnancy shouldn’t be a pathway to ill health. Yet despite facing a much higher risk of type 2 diabetes, too many women with GDM receive little or no follow-up care after pregnancy.

“As the Government turns its Strategy into action, support for women who have had gestational diabetes must not be overlooked.”

Last year, the NHS published the first national GDM audit for England in 2024/25, which revealed inconsistencies in follow-up care.

Only 57 per cent of women with GDM received an annual HbA1c test, which should be offered to every woman with GDM.

An HbA1c test measures average blood sugar levels over the previous two to three months.

Only 4.5 per cent of women had received support through the NHS Diabetes Prevention Programme.

The report also found that 11 per cent of women developed prediabetes within five years of having GDM, while 15 per cent developed type 2 diabetes within 10 years.

Prediabetes means blood sugar levels are higher than normal and a person has a higher risk of developing type 2 diabetes.

A recent survey funded by Diabetes UK also found that more than a third of women with GDM felt abandoned by healthcare services after giving birth.

If you live in England and have had gestational diabetes, you can self-refer to the NHS Diabetes Prevention Programme, which supports people at risk of developing type 2 diabetes. If you live in Northern Ireland, Scotland or Wales, you can speak to your GP about support.

Diabetes UK has written to women’s health minister Baroness Merron calling for urgent improvements to postnatal support for those diagnosed with GDM during pregnancy.

GDM affects between 10 and 20 per cent of pregnant women, but Diabetes UK said cases have long been underreported and UK-wide data on the condition has not been readily available.

The charity said poor follow-up care for women who have had GDM may be contributing to rising rates of type 2 diabetes in younger women.

It is calling for consistent postnatal follow-ups for women after GDM, more referrals to the NHS Diabetes Prevention Programme, greater accountability for improvements in postnatal care, and action on inequalities affecting women from deprived and minority ethnic communities.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.